Belite Bio (BLTE) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Belite Bio (BLTE) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 100.9% versus a loss of 1.1%. Belite Bio is the larger company by market cap ($6.29 billion vs $5.28 billion), about 1.2 times the size. On valuation, PTC Therapeutics trades at a lower forward P/E (23.6x vs 69.1x for Belite Bio).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | PTCT |
|---|---|---|
| Share price | $156.08 | $63.23 |
| Market cap | $6.29B | $5.28B |
| 1-day change | +0.30% | -0.74% |
| YTD return | -2.79% | -16.76% |
| 1-year return | +100.90% | -1.06% |
| 5-year return | — | +66.00% |
| Forward P/E | 69.06 | 23.62 |
| EPS (TTM) | $-2.74 | $-0.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.73B |
| Revenue growth (YoY) | — | +114.51% |
| Net income (latest FY) | $-77.61M | $682.64M |
| Operating margin | — | 50.09% |
| Net margin | — | 39.44% |
| 52-week high | $200.00 | $90.87 |
| 52-week low | $76.50 | $61.23 |
| Distance from 52-week high | -21.96% | -30.42% |
| Analyst consensus | none | buy |
| Avg. price target upside | +46.65% | +60.98% |
| Average volume | 182.25K | 1.15M |
| Shares outstanding | 40.27M | 83.46M |
| Employees | 41 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLTE has outperformed PTCT by 102.0 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
BLTE vs PTCT FAQ
Which is bigger, Belite Bio or PTC Therapeutics?
Belite Bio (BLTE) is larger, with a market capitalization of $6.29B compared with $5.28B for PTC Therapeutics (PTCT).
Which stock has performed better over the past year, BLTE or PTCT?
BLTE returned +100.90% over the past 12 months, compared with -1.06% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.